Efficacy of oral prolonged-release mesalazine in moderately active ulcerative colitis

Kristine Paridaens; John R Fullarton; Simon P L Travis

doi:10.1002/jgh3.12935

Efficacy of oral prolonged-release mesalazine in moderately active ulcerative colitis

JGH Open. 2023 Jul 7;7(7):516-519. doi: 10.1002/jgh3.12935. eCollection 2023 Jul.

Authors

Kristine Paridaens¹, John R Fullarton², Simon P L Travis³

Affiliations

¹ Medical Affairs Ferring International Center St-Prex Switzerland.
² HEOR Violicom Medical Limited Aldermaston UK.
³ NIHR Oxford Biomedical Research Centre Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital Oxford UK.

Abstract

New meta-analyses are presented that provide further evidence supporting the effectiveness of oral prolonged-release mesalazine compared to other oral mesalazines as induction therapy in patients with moderately active ulcerative colitis.

Keywords: aminosalicylates; delayed‐release; effectiveness; inflammatory bowel disease; mesalamine.